A clinical trial has for the first time proven that an antibody called J591 specifically targets an antigen found in high amounts on both prostate tumors and on blood vessels of all solid tumors, according to a study by medical researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.>>> Discuss This Story
